Take a look at the presentations from our Research & Development (R&D) Day on AI-Immunology™ captured in a series of videos. 

In this interview with BioStock, our CEO, Christian Kanstrup, discusses his vision for Evaxion, delving into AI, cancer, and partnerships.

In this presentation, Professor Adnan Khattak will set the scene by introducing participants to the medical field of malignant melanoma and the need that Evaxion’s personalized cancer vaccines is trying to meet. 

Watch Evaxion founder Andreas Holm Mattson talk about EDEN validation and partnerships

Watch CEO Per Norléns interview for Redeye Growth Day 2023

Take a look at the highlights from our first-ever Research & Development (R&D) Day captured in a series of video presentations.

In a 7 minutes conversation with Redeye, our CEO Per Norlén explains how leftovers from ancient viruses that infected our ancestors, so-called ERVs, can help us develop an efficient cancer treatment today and in the future.

Our CEO, Per Norlén, presented at Redeye Fight Cancer on January 19, 2023.

Redeye interviewed Evaxion’s newly appointed CEO, Per Norlén, about his background, reasons for joining the company, and hopes for the future

Our CEO, Per Norlén, presented the company at BioStock Life Science Fall Summit 2022 in Lund, Sweden. In the video, you can hear more about how we use the power of our AI  to make a unique and personalized treatment for each patient